Sulphanilamide in the Treatment of Erysipelas.
作者信息
Snodgrass W R, Anderson T
出版信息
Br Med J. 1937 Dec 11;2(4014):1156-9. doi: 10.1136/bmj.2.4014.1156.
Abstract
摘要
相似文献
1
Sulphanilamide in the Treatment of Erysipelas.磺胺治疗丹毒
Br Med J. 1937 Dec 11;2(4014):1156-9. doi: 10.1136/bmj.2.4014.1156.
2
Sulphanilamide in Erysipelas.丹毒中的磺胺
Br Med J. 1938 Aug 20;2(4050):399-403. doi: 10.1136/bmj.2.4050.399.
3
Potential for natural and enhanced attenuation of sulphanilamide in a contaminated chalk aquifer.受污染白垩含水层中磺胺的自然衰减和强化衰减潜力
J Environ Sci (China). 2017 Dec;62:39-48. doi: 10.1016/j.jes.2017.08.010. Epub 2017 Aug 30.
4
[How I prevent erysipelas and its consequences and recurrences].
Rev Med Liege. 2004 Jul-Aug;59(7-8):423-5.
5
Food handler's infection (swine erysipelas) in man.人感染食品从业人员感染病（猪丹毒）
Calif Med. 1949 Jun;70(6):486-8.
6
[Etiology of erysipelas].
Wien Klin Wochenschr. 1987 Feb 20;99(4):105-7.
7
8
[Compression is important in erysipelas treatment].[压迫在丹毒治疗中很重要]。
Ugeskr Laeger. 2017 Oct 9;179(41).
9
Erysipelas in the elderly: Are the concerns and economic burden increasing? Apropos of a case.
Acta Dermatovenerol Alp Pannonica Adriat. 2011 Jun;20(2):63-6.
10
Photo-oxidation of sulphanilamide to blue product.磺胺的光氧化生成蓝色产物。
Pak J Pharm Sci. 1989 Jul;2(2):13-7.
引用本文的文献
1
Can the Future of ID Escape the Inertial Dogma of Its Past? The Exemplars of Shorter Is Better and Oral Is the New IV.身份识别的未来能否摆脱其过去的惯性教条？“越短越好”以及“口服是新的静脉注射”的范例。
Open Forum Infect Dis. 2022 Dec 29;10(1):ofac706. doi: 10.1093/ofid/ofac706. eCollection 2023 Jan.
2
Pioneering controlled trials of treatments for erysipelas and pneumonia in Glasgow, 1936-1947.1936年至1947年在格拉斯哥进行的丹毒和肺炎治疗的开创性对照试验。
J R Soc Med. 2019 Jul;112(7):304-312. doi: 10.1177/0141076819856278.
3
Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases.患者报告结局评估作为传染病研究的终点指标
Clin Infect Dis. 2016 Aug 15;63 Suppl 2(Suppl 2):S52-6. doi: 10.1093/cid/ciw317.
4
Early Response in Cellulitis: A Prospective Study of Dynamics and Predictors.蜂窝织炎的早期反应：一项关于动态变化和预测因素的前瞻性研究
Clin Infect Dis. 2016 Oct 15;63(8):1034-1041. doi: 10.1093/cid/ciw463. Epub 2016 Jul 11.
5
Why the MRC therapeutic trials committee did not introduce controlled clinical trials.医学研究委员会治疗性试验委员会为何未引入对照临床试验。
J R Soc Med. 2015 Dec;108(12):499-511. doi: 10.1177/0141076815618891.
6
Treatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department setting.急诊科环境下急性细菌性皮肤和皮肤结构感染抗生素治疗随机对照试验的治疗结局指标。
Int J Emerg Med. 2015 Apr 22;8:11. doi: 10.1186/s12245-015-0060-9. eCollection 2015.
7
Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.系统评价与Meta分析以评估急性细菌性皮肤和皮肤结构感染的抗菌治疗效果。
Antimicrob Agents Chemother. 2015 Aug;59(8):4510-20. doi: 10.1128/AAC.00679-15. Epub 2015 May 18.
8
UK Medical Research Council and multicentre clinical trials: from a damning report to international recognition.英国医学研究理事会与多中心临床试验：从一份严厉的报告到国际认可。
J R Soc Med. 2013 Dec;106(12):498-509. doi: 10.1177/0141076813510452.
9
The FDA reboot of antibiotic development.美国食品药品监督管理局重启抗生素研发。
Antimicrob Agents Chemother. 2013 Oct;57(10):4605-7. doi: 10.1128/AAC.01277-13. Epub 2013 Jul 29.
10
Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.头孢洛林酯治疗社区获得性细菌性肺炎和急性细菌性皮肤和皮肤结构感染。
Drugs. 2012 Jul 30;72(11):1473-93. doi: 10.2165/11635660-000000000-00000.
Zotero 插件